Oestrogen modulator reduces risk of breast cancerBMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7200.1717a (Published 26 June 1999) Cite this as: BMJ 1999;318:1717
- Scott Gottlieb
- New York
The selective oestrogen receptor modulator raloxifene, currently licensed to treat osteoporosis in postmenopausal women, significantly reduced the risk of breast cancer, according to a study published this week.
In the three year multicentre trial 7705 women below the age of 81 years were randomised to raloxifene or placebo and followed for a median of 40 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial